For Investors
Our Motivation
Bringing a drug to market can cost up to $2B, yet clinical trials yield a 90% failure rate. Why? Current tools and assays can’t accurately predict how a drug will act once it enters a patient’s body. Even when drugs receive FDA approval, adverse drug reactions are the fourth leading cause of death in America. On top of that, up to 60% of prescribed medications are ineffective.
Syntensor helps drug developers address both these challenges. They’re building models designed to better predict toxicity or lack of efficacy, the key causes of clinical trial failure, before the trials start. Improving the efficacy and safety of new medications could save companies billions of dollars in R&D costs. It could also save lives.
Our Business Model
Syntensor aims to revolutionize drug development by creating advanced simulation tools akin to the “CAD for biology.” Our goal is to drastically reduce high failure rates in clinical trials and mitigate adverse drug reactions. We are also working to make our simulator generalizable across applications, creating a foundation model for biology and opening the door to a SaaS-like business model.